Compare CRGO & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRGO | PLRX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | Spain | United States |
| Employees | 382 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.7M | 68.7M |
| IPO Year | N/A | 2020 |
| Metric | CRGO | PLRX |
|---|---|---|
| Price | $1.23 | $1.09 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 4 |
| Target Price | $2.40 | ★ $2.67 |
| AVG Volume (30 Days) | 55.8K | ★ 706.8K |
| Earning Date | 05-26-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.61 | N/A |
| Revenue Next Year | $16.85 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.17 | $1.05 |
| 52 Week High | $4.24 | $1.95 |
| Indicator | CRGO | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.22 | 40.45 |
| Support Level | $1.17 | N/A |
| Resistance Level | $1.45 | $1.37 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 26.11 | 19.23 |
Freightos Ltd operates as a vendor-neutral booking and payment platform for international freight. Its platform supports supply chain efficiency and agility by enabling real-time procurement of ocean and air shipping across more than ten thousand importers/exporters, thousands of forwarders, and dozens of airlines and ocean carriers. The company operates in two segments: the Platform segment and the Solutions segment. The majority of the revenue is derived from the Solutions segment, which provides software tools and data to help industry participants automate their pricing, sales, and procurement processes. Geographically, it generates the maximum revenue from Europe, and the rest from the United States, Hong Kong and Others.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.